An experimental vaccine meant to protect against nine types of human papillomavirus (HPV) could prevent 90 percent of all cervical cancers, a new study suggests.
Researchers examined data from more than 2,500 women with precancerous cervical lesions and found that nearly all were caused by the nine types of HPV targeted by the vaccine being developed by Merck and Co.
The new vaccine, currently undergoing clinical trials, protects against more types of HPV than current vaccines, according to the study published Oct. 1 in the journal Cancer Epidemiology, Biomarkers & Prevention.
Study mentioned:
Cancer Epidemiol Biomarkers Prev. 2014 Oct 2. pii: cebp.0566.2014. [Epub ahead of print]
Evaluation of Human Papillomavirus Type Replacement Post-vaccination Must Account for Diagnostic Artifacts: Masking of HPV52 by HPV16 in Anogenital Specimens.
No comments:
Post a Comment